- Leading Chinese life science park partners with QIAGEN to advance biomarker R&D and develop products with Pharma companies and institutes
- QIAGEN expands in top emerging market and adds to pipeline of valuable content in Personalized Healthcare
- Translational focus builds on QIAGEN's expertise across R&D life cycle and BioBAY's strategic position in Chinese biotech industry
SUZHOU, China, and HILDEN, Germany, May 24, 2013 ‹ QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and SIP Biotech Development Co., Ltd. (BioBAY) today announced the opening of QIAGEN (Suzhou) Translational Medicine Center, a translational medicine R&D Corporation which aims to accelerate the discovery and validation of biomarkers, and to create companion diagnostics for the Chinese market. QIAGEN (Suzhou) is a joint venture of QIAGEN and BioBAY, the innovative life sciences cluster in Suzhou Industrial Park near Shanghai. The companies announced the launch of QIAGEN (Suzhou) today in an opening ceremony on the BioBAY campus, which currently hosts more than 330 companies and research groups.
QIAGEN (Suzhou) will provide services and consulting with state-of-the-art QIAGEN molecular technologies for international and Chinese pharmaceutical companies, as well as research institutes to enable translational medicine, the multidisciplinary process of advancing discoveries from laboratory bench to the patient's bedside. The center will work with partners located at BioBAY and elsewhere in China to provide fully integrated biomarker solutions to accelerate drug development, as well as to commercialize companion diagnostics. The four key service sections include biobanking, pharmacogenetics, next generation sequencing (NGS) and pharmacogenomics. This innovative alliance builds on QIAGEN's leading global position in Personalized Healthcare, using genomic information to produce individualized treatment decisions for patients. QIAGEN (Suzhou) is expected to grow to about 50 employees within three years.
"We are delighted to join with BioBAY, a strategically positioned biotechnology partner, in the mission of creating novel molecular diagnostics to meet pressing medical needs for patients. QIAGEN continues to expand our relationships in China, one of our most important countries in sales and a key growth market for us," said Dr. Victor Shi, President of QIAGEN Asia Pacific. "Partnering with BioBAY expands our commitment to translational research in biomarkers and companion diagnostics for China and other markets. Pharma and biotech companies in China's dynamic market face special needs that we can address through this unique translational medicine collaboration, helping to accelerate the development of companion diagnostics. Personalized Healthcare matches important new drugs with the right patients and creates better treatment benefits."
"BioBAY is very pleased to welcome QIAGEN to our Suzhou campus, where scientists, technology platforms and ideas from more than 320 companies and institutes can interact. QIAGEN's expertise in developing personalized treatment strategies using companion diagnostics is transforming the practice of medicine and improving life for patients. We expect the new collaborations with multinational companies and China's life sciences sector to lead to important new products," said Yuwen Liu, CEO of BioBAY.
QIAGEN and BioBAY also announced the leadership of QIAGEN (Suzhou): Dr. Peizhuo Zhang, an experienced biomedical entrepreneur who has collaborated extensively with international companies, will serve as General Manager of QIAGEN (Suzhou). Dr. Jean-Claude Muller, a French national who has 40 years of experience as a scientist and senior executive in global pharmaceutical R&D, will join the Board of Directors as an Independent Director and an Advisor. His last position was Senior Vice-President R&D, Prospective & Strategic Initiatives, Sanofi-Aventis.
Globally, QIAGEN is at the forefront of developing and validating a range of tests that provide physicians with an individual patient's molecular information to select the most appropriate medicines. The company already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan, and more than 15 projects are under way to co-develop and market companion diagnostics with leading pharmaceutical and biotech companies. Learn more about Personalized Healthcare at www.qiagen.com/overview/companiondiagnostics/.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2013, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com/.
BioBAY is located in Dushu Lake Higher Education Town of Suzhou Industrial Park (SIP). Suzhou Industrial Park (SIP), the most important cooperation program between China and Singapore, is committed to building a globally competitive high-tech industrial park. BioBAY is a key driver for innovation, and is a leader in the development of life science throughout China. More than 330 high-tech innovation companies covering drug discovery, medical device (including IVD), biotech and nanotech, have been located in BioBAY, as well as Cold Spring Harbor Asia Conference Center, and scientists and professionals have come to join this dynamic innovative community. For more information, please visit: www.biobay.com.cn.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, new product developments, new product launches, regulatory submissions, and financing plans are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Contact, Corporate Communications:
Dr. Thomas Theuringer
Director Public Relations
+49 2103 29 11826
+1 240 686 7425
Communications Manager Asia
+86 21 3865 3824
VP Head of Corporate Communications
+49 2103 29 11711
+1 240 686 2222
Director, Global Investor Relations
+1 240 686 7400